- Review the diagnostic criteria, phenotypes, and variants of MS and related disorders to promote more accurate diagnosis and institution of appropriate therapy.
- Identify the roles and interactions of genetics, epigenetics, the microbiome, environmental factors, pregnancy, age, comorbidities, and risk behaviors in determining MS susceptibility, disease course, and prognosis to improve understanding of the potential cause and modifiers of the disease.
- Integrate information about the overlapping and distinct inflammatory and degenerative mechanisms underlying MS relapses, progression, and white and gray matter pathology as the basis for monitoring and treating the disease.
- Summarize methods to monitor MS disease activity and severity, including patient self-report and automated self-assessment, new clinician-reported outcomes, standard and advanced imaging, and biomarkers to optimize their utilization in clinical practice and clinical research.
- Synthesize emerging data on treatment strategies, such as early treatment, switching therapies, treating-to-target of no evidence of disease activity, personalized treatment, and post-marketing monitoring of safety and efficacy to more effectively manage disease therapy in practice.
- Review the design and results of recent clinical trials in relapsing and progressive MS, including anti-inflammatory, neuroprotective, and repair-promoting strategies, to prepare clinicians for their incorporation into practice in an evidence-based manner.
- Integrate treatment of symptoms, multidisciplinary management of the sequelae of MS, and rehabilitative strategies into clinical care to improve patients’ function and quality of life.
- Critically examine how the expert patient, news media, social media, and health policy affect the relationships between patients with MS, health care providers, and researchers.